Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

James R. Berenson, MD, Noemi Silagan, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, Eli Forouzan, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Ralph V. Boccia, MD, Honghao Hank Yang, Stephen Lim, MD, Robert Vescio, MD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-143005

Published: 2020

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

James R. Berenson, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, MBA, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Youram Nassir, MD, Ravindranath Patel, MD, Alberto Bessudo, MD, Daniel Greenwald, MD, Ralph V. Boccia, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2019) 134 (Supplement_1): 1903.

https://doi.org/10.1182/blood-2019-131370

Published: 2019

Journal Articles

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Tanya M. Spektor, PhD, Tahmineh Safaie, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S. Wang, BS, Ning Xu, PhD, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1786.

https://doi.org/10.1182/blood-2019-132012

Published: 2019

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients

James R Berenson, MD, To Jennifer, BS, Tanya M. Spektor, PhD, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Alberto Bessudo, MD, Ravindranath Patel, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2018) 132 (Supplement 1): 1988.

https://doi.org/10.1182/blood-2018-99-119274

Published: 2018

Journal Articles

Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone

Sean Bujarski, BA, Camilia Soof, BS, Mingjie Li, BS, Cathy S. Wang, BS, Eric Sanchez, BA, Marsiye Emamy-Sadr, Regina Swift, Kian Rahbari, Saurabh Patil, BS, Tanya M. Spektor, PhD, Haiming Chen, MD PhD, James R. Berenson, MD

Blood (2018) 132 (Supplement 1): 1894.

https://doi.org/10.1182/blood-2018-99-119190

Published: 2018

Journal Articles

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

James R Berenson, MD, Alexa Cohen, Tanya M. Spektor, PhD, Ashkan Lashkari, MD, Roy Mackintosh, MD, Alberto Bessudo, MD, Haresh Jhangiani, Nashat Gabrail, MD, Ibrahim Nakhoul, MD, Samir Kubba, MD, Jeffrey D. Neidhart, MD BS, Maluso Tina, Regina Swift, Robert Vescio, MD

Blood (2017) 130 (Supplement 1): 3106.

https://doi.org/10.1182/blood.V130.Suppl_1.3106.3106

Published: 2017

Journal Articles

Serum CD147 Levels Are Increased in Multiple Myeloma Patients and Elevated Levels Are Associated with Refractory Disease and Shortened Progression Free Survival

Zachary Gross, MD, Kyle Udd, BA, Matthew Ghermezi, Soudabeh Etessami, PhD, Haiming Chen, MD PhD, Tanya M. Spektor, PhD, Mingjie Li, BS, George Tang, PhD, Cathy S Wang, BS, Eric Sanchez, BA, Camilia M Soof, BS, Christian E Casas, BS, Regina Swift, RN, James R. Berenson, MD

Blood (2016) 128 (22): 5652.

https://doi.org/10.1182/blood.V128.22.5652.5652

Published: 2016

Journal Articles

Plasma B-Cell Maturation Antigen Levels Are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia

Kyle A Udd, BA, Laura Z. Rassenti, PhD, Michael E David, BA, James Wang, MD, Suzie Vardanyan, MS, Julia Linesch, Mingjie Li, BS, Eric Sanchez, BA, Haiming Chen, MD PhD, Tanya M. Spektor, PhD, Thomas J. Kipps, MD, PhD, James Berenson, MD

Blood (2015) 126 (23): 2931.

https://doi.org/10.1182/blood.V126.23.2931.2931

Published: 2015

Journal Articles

Serum Levels of B-Cell Maturation Antigen Are Elevated in Waldenström's Macroglobulinemia Patients and Correlate with Disease Status and Conventional M-Protein and IgM Levels

Suzie Vardanyan, MS, Kirsten Meid, MPH, Kyle A Udd, BA, James Wang, MD, Mingjie Li, BS, Eric Sanchez, BA, Cathy Wang, BS, Abigail Gillespie, Maya Spitzer, Tanya M. Spektor, PhD, Anna Shvartsur, Nika Manik Harutyunyan, Gigi Garzio, George Tang, PhD, Haiming Chen, MD PhD, Steven P Treon, MD PhD, James Berenson, MD

Blood (2015) 126 (23): 1778.

https://doi.org/10.1182/blood.V126.23.1778.1778

Published: 2015

Journal Articles

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

James Berenson, MD, Laura Stampleman, MD, Alberto Bessudo, MD, Peter J Rosen, MD, Leonard M. Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Swift A Regina, RN, Wang James, Eades Benjamin, PharmD, Tanya M. Spektor, PhD, Robert Vescio, MD

Blood (2015) 126 (23): 5383.

https://doi.org/10.1182/blood.V126.23.5383.5383

Published: 2015

NARROW

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients

Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

Serum CD147 Levels Are Increased in Multiple Myeloma Patients and Elevated Levels Are Associated with Refractory Disease and Shortened Progression Free Survival

Plasma B-Cell Maturation Antigen Levels Are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia

Serum Levels of B-Cell Maturation Antigen Are Elevated in Waldenström's Macroglobulinemia Patients and Correlate with Disease Status and Conventional M-Protein and IgM Levels

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only